INT47425

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.81
First Reported 1980
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 6.70
Pain Relevance 1.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Chrna7) plasma membrane (Chrna7) cytoplasm (Chrna7)
Anatomy Link Frequency
axillary 1
cholinergic neurons 1
lateral 1
saliva 1
limb 1
Chrna7 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
GABAergic 5 93.68 High High
antagonist 5 92.16 High High
Botox 34 91.52 High High
Glutamate 3 90.04 High High
Piles 27 89.84 High High
substance P 5 89.36 High High
Analgesic 3 83.60 Quite High
Inflammation 5 81.20 Quite High
long-term potentiation 39 79.48 Quite High
sodium channel 1 79.12 Quite High
Disease Link Frequency Relevance Heat
Overactive Bladder 71 100.00 Very High Very High Very High
Rhinitis 2 99.96 Very High Very High Very High
Skin Appendage Disease 9 99.76 Very High Very High Very High
Fistula 2 99.48 Very High Very High Very High
Hidrocystoma 2 99.10 Very High Very High Very High
Syndrome 1 98.52 Very High Very High Very High
Disease 15 98.50 Very High Very High Very High
Dystonia 39 97.80 Very High Very High Very High
Eczema 8 95.96 Very High Very High Very High
Lichen 3 94.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Quantitative analysis revealed different modes of lateral diffusion of alpha7-nAChR dependent on their subcellular localization.
Localization (localization) of alpha7-nAChR in lateral
1) Confidence 0.81 Published 2010 Journal PLoS ONE Section Abstract Doc Link 20634896 Disease Relevance 0.08 Pain Relevance 0.16
General contraindications for the use of BTX have to be considered before its use [Table 2].[7]

PROCEDURE OF BTX ADMINISTRATION

Localization (use) of BTX
2) Confidence 0.61 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840903 Disease Relevance 0.49 Pain Relevance 0.22
In patients suffering from Frey's syndrome, lower doses are needed as compared to axillary hyperhidrosis and longer durations have been obtained.[13]

BTX: CENTRAL NERVOUS SYSTEM (CNS) EFFECTS

Localization (durations) of BTX in axillary associated with skin appendage disease and syndrome
3) Confidence 0.55 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.73 Pain Relevance 0.33
Botulinum toxin (BTX), a highly specific toxin, blocks the release of acetylcholine from cholinergic neurons.
Localization (release) of BTX in cholinergic neurons
4) Confidence 0.43 Published 2002 Journal BMC Gastroenterol Section Body Doc Link PMC122056 Disease Relevance 0.75 Pain Relevance 0.08
In Hailey-Hailey disease, facial eccrine hidrocystomas, salivary fistulas, and intrinsic rhinitis, BTX-A blocks the secretion of sweat/saliva/mucus.
Localization (secretion) of BTX in saliva associated with rhinitis, fistula, hidrocystoma and disease
5) Confidence 0.34 Published 2005 Journal J Cosmet Dermatol Section Abstract Doc Link 17168867 Disease Relevance 1.16 Pain Relevance 0.30
Characterization of its action and that of tityustoxin on synaptosomal accumulation and release of acetylcholine.
Localization (release) of beta-Bungarotoxin
6) Confidence 0.31 Published 1980 Journal Biochim. Biophys. Acta Section Title Doc Link 7353009 Disease Relevance 0 Pain Relevance 0.13
Localization and dose of BtxA injections was determined individually based on clinical examination as well as EMG in patients with limb dystonia.
Localization (Localization) of BtxA in limb associated with dystonia
7) Confidence 0.18 Published 2002 Journal J. Neurol. Section Abstract Doc Link 11993530 Disease Relevance 1.49 Pain Relevance 0
In Hailey-Hailey disease, facial eccrine hidrocystomas, salivary fistulas, and intrinsic rhinitis, BTX-A blocks the secretion of sweat/saliva/mucus.
Localization (secretion) of BTX in sweat associated with rhinitis, fistula, hidrocystoma and disease
8) Confidence 0.11 Published 2005 Journal J Cosmet Dermatol Section Abstract Doc Link 17168867 Disease Relevance 1.16 Pain Relevance 0.30
BTX is not approved for the treatment of OAB but is now widely used in patients who are refractory to conventional antimuscarinic therapy or who do not tolerate it due to systemic side effects.
Localization (used) of BTX associated with overactive bladder
9) Confidence 0.06 Published 2010 Journal F1000 Med Rep Section Body Doc Link PMC2948402 Disease Relevance 0.68 Pain Relevance 0.04
Clinical results in patients before and after BTX treatment
Localization (treatment) of BTX
10) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.15 Pain Relevance 0.19
This article expands the proposed etiology to include presynaptic, synaptic, and postsynaptic mechanisms of abnormal depolarization (ie, excessive release of acetycholine [ACh], defects of acetylcholinesterase, and upregulation of nicotinic ACh-receptor activity, respectively).
Localization (release) of acetycholine
11) Confidence 0.00 Published 2004 Journal J Am Osteopath Assoc Section Abstract Doc Link 15233331 Disease Relevance 0 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox